Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Desmopressin (DDAVP) affects haemostasis by the release of von Willebrand factor and coagulation factor VIII from endothelium. The aim of the study was to evaluate the results of DDAVP testing in paediatric patients with congenital bleeding disorders. Forty-one patients consisting of children with von Willebrand's disease (VWD, n = 26) and platelet function defects (PFD, n = 15) received DDAVP intravenously at a dosage of 0.3 mug/kg over 30 min. FVIII activity (FVIII), von Willebrand factor antigen (VWF:Ag), collagen-binding activity (VWF:CB) and PFA 100((R)) closure times (CT) were measured before, 60, 120 and 240 min after DDAVP. In VWD, the VWF:Ag increased threefold until 60 min and then it decreased continuously. Compared with baseline, VWF:Ag was significantly higher at 60 and 120 min but not at 240 min. In contrast, in PFD, the peak of VWF:Ag was reached after 120 min. Two hundred and forty minutes after DDAVP, the mean was still significantly elevated compared with baseline values. The course of VWF:CB corresponded to that of VWF:Ag. In patients with VWD and PFD, FVIII rose two- to threefold within 2 h after DDAVP. CT in patients with VWD shortened markedly within 120 min and then rose again. In all children with PFD, except one non-responder, the CT shortened within 240 min after DDAVP. Two non-responders with VWD were identified by the failed increase of VWF:Ag, VWF:CB and by prolonged CT. Haemostatic effects of DDAVP differ interindividually and dependent on the coagulation disorder. DDAVP was effective in most, but not in all patients. DDAVP testing is recommended to determine the individual haemostatic response.
Hanebutt
F L
FL
Department of Pediatric Hematology and Oncology, University Hospital Carl Gustav Carus of Technical University Dresden, Dresden, Germany.
Rolf
N
N
Loesel
A
A
Kuhlisch
E
E
Siegert
G
G
Knoefler
R
R
D000293:Adolescent; D001760:Bleeding Time; D001779:Blood Coagulation Factors / Q000187:drug effects / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D020147:Coagulation Protein Disorders / Q000097:blood / Q000188:drug therapy*; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000494:pharmacology*; D004341:Drug Evaluation; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006490:Hemostatics / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012189:Retrospective Studies; D013997:Time Factors; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy*
D001779:Blood Coagulation Factors; D006490:Hemostatics; D003894:Deamino Arginine Vasopressin